In this conversation, David Crean, Chief Business Officer of Medici Nova, shares his journey from academia to the biopharmaceutical industry. He discusses his early career, pivotal moments, and the unique business model of MediciNova, which focuses on addressing unmet medical needs in challenging diseases like ALS. Crean emphasizes the importance of capital efficiency in drug development and outlines the exciting projects currently underway at MediciNova, highlighting the potential impact on patients.

MediciNova Website - https://medicinova.com/

Nano Cap Podcast - https://www.nanocappod.com/

Takeaways

• David Crean transitioned from academia to the biopharmaceutical industry.

• He values education and holds both a PhD and an MBA.

• MediciNova focuses on unmet medical needs, particularly in ALS.

• The company operates with a unique, capital-efficient business model.

• Crean emphasizes the importance of strategic corporate finance and development.

• He has a strong interest in drug commercialization and development.

• MediciNova has a pipeline of promising compounds with existing data.

• The company is close to finalizing patient enrollment for key trials.

• Crean is excited about the potential impact of their drugs on patients.

DISCLAIMER - The contents of this podcast are for informational purposes only and do not constitute financial, investment, legal, or other professional advice. Listeners should not construe any information discussed as a recommendation to buy, sell, or hold any securities or investments. Always consult with a qualified financial advisor or professional before making any financial decisions.